BioCryst Pharmaceuticals
BCRX
233 hedge funds and large institutions have $2.09B invested in BioCryst Pharmaceuticals in 2022 Q1 according to their latest regulatory filings, with 50 funds opening new positions, 67 increasing their positions, 71 reducing their positions, and 21 closing their positions.
164% more call options, than puts
Call options by funds: $92M | Put options by funds: $34.8M
138% more first-time investments, than exits
New positions opened: 50 | Existing positions closed: 21
50% more funds holding in top 10
Funds holding in top 10: 4 → 6 (+2)
29% more capital invested
Capital invested by funds: $1.62B → $2.09B (+$470M)
13% more funds holding
Funds holding: 206 → 233 (+27)
3.21% more ownership
Funds ownership: 66.01% → 69.22% (+3.2%)
6% less repeat investments, than reductions
Existing positions increased: 67 | Existing positions reduced: 71
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$72.5M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$60.9M |
| 3 |
Victory Capital Management
San Antonio,
Texas
|
+$49.9M |
| 4 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
+$37.2M |
| 5 |
ACA
Avoro Capital Advisors
New York
|
+$30.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Sarissa Capital Management
Greenwich,
Connecticut
|
-$42.5M |
| 2 |
HM
HealthCor Management
New York
|
-$34.5M |
| 3 |
SI
Sofinnova Investments
Menlo Park,
California
|
-$20.9M |
| 4 |
Two Sigma Investments
New York
|
-$16.4M |
| 5 |
BCPEMI
Bain Capital Public Equity Management II
Boston,
Massachusetts
|
-$14.6M |
BCRX Hedge Fund Activity: Q1 2022 in Review
233 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in BioCryst Pharmaceuticals (BCRX) for Q1 2022, worth a combined $2.09B — up 29% from $1.62B a quarter earlier.
Buyers outnumbered sellers: 50 funds opened new BCRX positions and 21 closed out — a net gain of 29 holders — while 67 added to existing stakes and 71 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $72.5M. The largest seller was Sarissa Capital Management, cutting an estimated $42.5M.
- 233 institutional investors held BioCryst Pharmaceuticals (BCRX) as of Q1 2022, up from 206 in Q4 2021.
- Funds reported $2.09B of BioCryst Pharmaceuticals stock for Q1 2022, up 29% quarter-over-quarter.
- 50 funds opened new BioCryst Pharmaceuticals positions in Q1 2022 and 21 closed out, a net change of +29 holders.
- The largest BioCryst Pharmaceuticals buyer in Q1 2022 was Fidelity Investments, an estimated $72.5M added.
- The largest BioCryst Pharmaceuticals seller in Q1 2022 was Sarissa Capital Management, an estimated $42.5M sold.
Based on aggregated 13F filings for Q1 2022.